How does brazikumab work?
The white blood cells that make up your immune system use different types of proteins, called interleukins, to send messages to each other. These proteins help to organize immune responses. In Crohn’s disease, a particular kind of interleukin, called interleukin-23 (IL-23), attracts new white blood cells to areas of inflammation, making it worse. Brazikumab is designed to stick to IL-23. This helps to stop IL-23 from binding to white blood cells, meaning they can’t get involved in inflammation. If IL-23 is stopped from binding to white blood cells, that should significantly reduce the symptoms making patients feel better.